Telaprevir

Janessa Smith, Pharm.D. BCPS, Paul A. Pham, Pharm.D.
Telaprevir is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or purchase a subscription.

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

Pediatrics Central

-- The first section of this topic is shown below --

INDICATIONS

FDA

In combination with peg-interferon and ribavirin, telaprevir indicated for the treatment of HCV (genotype1) patients with compensated liver disease, including cirrhosis, who are treatment-naïve OR who have been previously treated with interferon-based regimen, but had no response, partial response, or relapsed (no longer available in U.S.)

-- To view the remaining sections of this topic, please or purchase a subscription --

Last updated: February 9, 2018

Citation

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Telaprevir ID - 540606 A1 - Pham,Paul,Pharm.D. AU - Smith,Janessa,Pharm.D. BCPS Y1 - 2018/02/09/ BT - Johns Hopkins ABX Guide UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540606/all/Telaprevir PB - The Johns Hopkins University DB - Pediatrics Central DP - Unbound Medicine ER -